Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00443313 · ClinicalTrials.gov registry record

Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
664
Enrollment target

NCT00443313: Completed study, sponsored by National Cancer Institute (NCI).

NCT00443313 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 664 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00443313 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
664 participants
Enrollment target

Study Summary

Background: * Cancer of the cervix (bottom third of the uterus, or womb) can be prevented by regular Pap tests (also called Pap smears), which check for changes in the cells of the cervix. Because many women in the United States have regular Pap smears, cervical cancer is not common in this country. However, the disease is common among women in the Mississippi Delta because of poor participation in screening programs. * The major causes of cervical cancer are persistent human papillomaviruses (HPV) infection by cancer-associated HPV types and lack of screening. These viruses cause an infection that often goes away by itself, but if it does not go away, over a long time lead to cervical cancer. HPV causes cervical abnormalities, which are detected by Pap smears and then treated. Objectives: -To determine whether an at-home self-collection method for obtaining cells from the cervix can be a simple, safe and inexpensive way to screen for cervical cancer for women who don t go to the health clinic regularly. Eligibility: * Women who reside in the counties of Leflore, Sunflower, Washington or Tallahatchie, Mississippi. * Women between 26 and 65 years of age who are not pregnant and who have not had a hysterectomy. Design: Screening study participants undergo the following: * The doctor takes a cervical sample using the same self-collection device that women will use at home to self-collect. * Pelvic examination and Pap test. For this test, the woman lies on an exam table and the doctor inserts an instrument called a speculum into the vagina, opening it to see the cervix. A special brush is used to take a few cells from the cervix. The cells are placed on a glass slide and sent to a lab for examination. * Cervical cell specimen collection using an at-home self-collection kit that participants will use at home after 2 weeks * At-home self-collection by participant after 2 weeks. * Referral to a doctor for follow-up care, if needed. * Colposcopy (see below) in all w

Trial Details

FieldValue
Enrollment Target 664 participants
Start Date 2007-01-24
Est. Completion 2015-06-25

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00443313

The ClinicalTrials.gov registry entry for NCT00443313 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 664 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00443313 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00443313 about?

NCT00443313 is a clinical study titled "Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta". Background: * Cancer of the cervix (bottom third of the uterus, or womb) can be prevented by regular Pap tests (also called Pap smears), which check for changes in the cells of the cervix. Because many women in the United States have regular Pap smears, cervical cancer is not common in this country...

What is the current status of trial NCT00443313?

This trial is currently completed. The enrollment target is 664 participants. The study started on 2007-01-24. Estimated completion is 2015-06-25.

Who is sponsoring clinical trial NCT00443313?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.